157 related articles for article (PubMed ID: 19675593)
1. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope.
Matsuda M; Yamamoto T; Matsumura A; Kaneda Y
Gene Ther; 2009 Dec; 16(12):1465-76. PubMed ID: 19675593
[TBL] [Abstract][Full Text] [Related]
2. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.
Matsushima-Miyagi T; Hatano K; Nomura M; Li-Wen L; Nishikawa T; Saga K; Shimbo T; Kaneda Y
Clin Cancer Res; 2012 Nov; 18(22):6271-83. PubMed ID: 23014529
[TBL] [Abstract][Full Text] [Related]
4. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
Kurooka M; Kaneda Y
Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
[TBL] [Abstract][Full Text] [Related]
5. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.
Kawaguchi Y; Miyamoto Y; Inoue T; Kaneda Y
Int J Cancer; 2009 May; 124(10):2478-87. PubMed ID: 19173282
[TBL] [Abstract][Full Text] [Related]
6. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
Kaneda Y; Nakajima T; Nishikawa T; Yamamoto S; Ikegami H; Suzuki N; Nakamura H; Morishita R; Kotani H
Mol Ther; 2002 Aug; 6(2):219-26. PubMed ID: 12161188
[TBL] [Abstract][Full Text] [Related]
7. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.
Kawano H; Komaba S; Kanamori T; Kaneda Y
BMC Med; 2007 Sep; 5():28. PubMed ID: 17883878
[TBL] [Abstract][Full Text] [Related]
8. 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma.
Nomura M; Shimbo T; Miyamoto Y; Fukuzawa M; Kaneda Y
Cancer Sci; 2013 Feb; 104(2):238-44. PubMed ID: 23134437
[TBL] [Abstract][Full Text] [Related]
9. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.
Ito M; Yamamoto S; Nimura K; Hiraoka K; Tamai K; Kaneda Y
J Gene Med; 2005 Aug; 7(8):1044-52. PubMed ID: 15756713
[TBL] [Abstract][Full Text] [Related]
10. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.
Tanaka M; Shimbo T; Kikuchi Y; Matsuda M; Kaneda Y
Int J Cancer; 2010 Apr; 126(8):1982-1991. PubMed ID: 19830690
[TBL] [Abstract][Full Text] [Related]
11. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.
Matsuda M; Nimura K; Shimbo T; Hamasaki T; Yamamoto T; Matsumura A; Kaneda Y
J Neurooncol; 2011 May; 103(1):19-31. PubMed ID: 20730616
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study.
Kiyohara E; Tanemura A; Nishioka M; Yamada M; Tanaka A; Yokomi A; Saito A; Sakura K; Nakajima T; Myoui A; Sakurai T; Kawakami Y; Kaneda Y; Katayama I
Cancer Immunol Immunother; 2020 Jun; 69(6):1131-1140. PubMed ID: 32047956
[TBL] [Abstract][Full Text] [Related]
13. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.
Tanemura A; Kiyohara E; Katayama I; Kaneda Y
Cancer Gene Ther; 2013 Nov; 20(11):599-605. PubMed ID: 24157924
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis in hormone-resistant human prostate cancer PC3 cells by inactivated Sendai virus.
Gao H; Gong XC; Chen ZD; Xu XS; Zhang Q; Xu XM
Biomed Environ Sci; 2014 Jul; 27(7):506-14. PubMed ID: 25073909
[TBL] [Abstract][Full Text] [Related]
15. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector.
Morishita N; Nakagami H; Morishita R; Takeda S; Mishima F; Terazono B; Nishijima S; Kaneda Y; Tanaka N
Biochem Biophys Res Commun; 2005 Sep; 334(4):1121-6. PubMed ID: 16134237
[TBL] [Abstract][Full Text] [Related]
16. Development of a transferrin receptor-targeting HVJ-E vector.
Shimbo T; Kawachi M; Saga K; Fujita H; Yamazaki T; Tamai K; Kaneda Y
Biochem Biophys Res Commun; 2007 Dec; 364(3):423-8. PubMed ID: 17961511
[TBL] [Abstract][Full Text] [Related]
17. HVJ liposomes and HVJ envelope vectors.
Kaneda Y
Cold Spring Harb Protoc; 2011 Oct; 2011(10):1281-9. PubMed ID: 21969614
[TBL] [Abstract][Full Text] [Related]
18. Development of tissue-targeting hemagglutinating virus of Japan envelope vector for successful delivery of therapeutic gene to mouse skin.
Kawachi M; Tamai K; Saga K; Yamazaki T; Fujita H; Shimbo T; Kikuchi Y; Nimura K; Nishifuji K; Amagai M; Uitto J; Kaneda Y
Hum Gene Ther; 2007 Oct; 18(10):881-94. PubMed ID: 17892442
[TBL] [Abstract][Full Text] [Related]
19. Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth.
Lee CH; Nishikawa T; Kaneda Y
Oncotarget; 2017 May; 8(21):35048-35060. PubMed ID: 28456782
[TBL] [Abstract][Full Text] [Related]
20. Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes.
Tashiro H; Aoki M; Isobe M; Hashiya N; Makino H; Kaneda Y; Ogihara T; Morishita R
J Mol Cell Cardiol; 2005 Sep; 39(3):503-9. PubMed ID: 16040050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
